Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

June 2018

Palatin Technologies Added to Russell 3000® Index

Jun 25, 2018, 04:56 ET CRANBURY, N.J., June 25, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has been added to the Russell 3000® Index as part of the annual …

Palatin Technologies Added to Russell 3000® Index Read More »

Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

PDUFA Target Action Date March 23, 2019 Triggers Milestone Payment to Palatin of $20 Million CRANBURY, N.J., June 4, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that the U.S. Food and …

Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA Read More »

Scroll to Top